| Ototoxicity N = 30 | No ototoxicity N = 47 | Univariate model | Multivariate modela | ||
---|---|---|---|---|---|---|
OR (95%CI) | P value | OR (95%CI) | P value | |||
Sex, female | 24 (80%) | 29 (61.7%) | 2.48 (0.85–7.24) | 0.096 | 4.96 (1.24–19.87) | 0.024 |
Age (years), median (IQR) | 61 (43–65) | 65 (51–72) | 0.98 (0.95–1.01) | 0.247 | 0.98 (0.94–1.02) | 0.297 |
Race | ||||||
 Caucasian | 22 (73.3%) | 29 (61.7%) | 1.71 (0.63–4.64) | 0.295 |  |  |
 South Asian | 1 (3.3%) | 1 (2.1%) | 1.59 (0.09–26.36) | 0.748 |  |  |
 East Asian | 6 (20%) | 16 (34%) | 0.48 (0.16–1.42) | 0.188 | 0.24 (0.06–0.95) | 0.042 |
 African | 1 (3.3%) | 1 (2.1) | 1.59 (0.09–26.36) | 0.748 |  |  |
Weekly dose AK per bodyweight (mg/kg/week), median (IQR)b | 29 (23.7–41.3) | 25.2 (21.8–29.4) | 1.05 (1.00–1.10) | 0.047 | 1.03 (0.98–1.09) | 0.248 |
Months on AK, median (IQR) | 11.5 (7–18.25) | 7 (4–10) | 1.04 (1.00–1.08) | 0.052 |  |  |
Total dose AK per bodyweight (g/kg), Median (IQR)c | 1.81 (0.85–3.13) | 0.74 (0.51–1.27) | 1.59 (1.08–2.33) | 0.018 | 1.62 (1.08–2.43) | 0.020 |
Total dose AK (g), Median (IQR)d | 77.3 (52.9–196.3) | 41.7 (25.6–67.5) | 1.01 (1.00–1.02) | 0.011 |  |  |
Repeated exposure to amikacin | 9 (30%) | 10 (21.3%) | 1.59 (0.56–1.52) | 0.388 |  |  |
Baseline weight (kg), Median (IQR) | 51.5 (41–66.5) | 55 (48–64) | 0.99 (0.96–1.03) | 0.712 |  |  |
Initial serum creatinine (umol/L), mean (SD) | 66.0 (56.7–74.0) | 63 (53–75) | 1.01 (0.97–1.04) | 0.656 |  |  |
Baseline disabling hearing impairment | 8 (26.7%) | 24 (51.1%) | 0.35 (0.13–0.94) | 0.037 | 0.54 (0.17–1.74) | 0.305 |
Current treatment with macrolides | 29 (96.7%) | 45 (95.7%) | 1.23 (0.11–14.87) | 0.839 |  |  |
Nephrotoxicity | 1 (3.6%) | 4 (8.5%) | 0.38 (0.04–3.58) | 0.398 |  |  |